| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/05/2011 | EP2371362A1 Co-enzyme Q10 formulations for treating cancer by intravenous administration |
| 10/05/2011 | EP2371361A1 Methods to mobilize progenitor/stem cells |
| 10/05/2011 | EP2370593A2 Methods for the treatment of infections and tumors |
| 10/05/2011 | EP2370582A2 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| 10/05/2011 | EP2370468A1 ANTI-cMET ANTIBODY |
| 10/05/2011 | EP2370464A1 Process for the modulation of the antagonistic activity of a monoclonal antibody |
| 10/05/2011 | EP2370454A1 Wdrpuh epitope peptides and vaccines containing the same |
| 10/05/2011 | EP2370447A1 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
| 10/05/2011 | EP2370442A1 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
| 10/05/2011 | EP2370437A1 Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| 10/05/2011 | EP2370431A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use |
| 10/05/2011 | EP2370424A1 Compounds useful as inhibitors of atr kinase |
| 10/05/2011 | EP2370417A2 Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
| 10/05/2011 | EP2370416A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth |
| 10/05/2011 | EP2370402A2 Compounds for treating proliferative disorders |
| 10/05/2011 | EP2370399A1 Glucose-peg conjugates for reducing glucose transport into a cell |
| 10/05/2011 | EP2370390A2 Isolate compounds from phaleria macrocarpa as anti cancer |
| 10/05/2011 | EP2370175A2 Methods of inhibiting quiescent tumor proliferation |
| 10/05/2011 | EP2370109A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms |
| 10/05/2011 | EP2370097A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide |
| 10/05/2011 | EP2370096A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine |
| 10/05/2011 | EP2370095A1 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine |
| 10/05/2011 | EP2370094A1 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |
| 10/05/2011 | EP2370091A2 Compositions and methods relating to mir-31 |
| 10/05/2011 | EP2370090A1 Treating neoplasms with neurotoxin |
| 10/05/2011 | EP2370079A2 Hsp90 inhibitors for therapeutic treatment |
| 10/05/2011 | EP2370076A2 Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor |
| 10/05/2011 | EP2294070B1 New phenanthrylphenol linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential antitumour agents and process for the preparation thereof |
| 10/05/2011 | EP2259792B1 Bone morphogenetic proteins for use in treating and preventing neuroblastomas |
| 10/05/2011 | EP2150553B1 Condensed heterocyclic compounds as inhibitors of protein kinases |
| 10/05/2011 | EP1989207B1 Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| 10/05/2011 | EP1966151B1 Polycyclic indazole derivatives that are erk inhibitors |
| 10/05/2011 | EP1960370B1 Pyridiazinone derivatives for tumour treatment |
| 10/05/2011 | EP1923463B1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen |
| 10/05/2011 | EP1920370B1 Magnetic drug, magnetic drug guidance system and magnetic drug design method |
| 10/05/2011 | EP1899329B1 Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
| 10/05/2011 | EP1874352B1 Photodynamic therapy using chemoluminescence and a ligand-photosensitiser conjugate |
| 10/05/2011 | EP1844077B1 Dr5 antibodies and uses thereof |
| 10/05/2011 | EP1828389B1 Sparc promoter mutations associated with drug resistance, and methods associated therewith |
| 10/05/2011 | EP1787991B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| 10/05/2011 | EP1687267B1 Modified mscl protein channel |
| 10/05/2011 | EP1653912B1 Vaccine immunotherapy for immune suppressed patients |
| 10/05/2011 | EP1575940B1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 10/05/2011 | EP1562577B1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by thalidomide |
| 10/05/2011 | EP1546136B1 Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them |
| 10/05/2011 | EP1463497B1 Treating muscle wasting with selective androgen receptor modulators |
| 10/05/2011 | EP1454903B9 Thiadiazoline derivatives for treating cancer |
| 10/05/2011 | EP1395279B1 Use of neublastin polypeptides for treating neuropathic pain |
| 10/05/2011 | EP1377680B1 Diagnosis and treatment of breast cancer based upon scn5a |
| 10/05/2011 | EP1377276B1 Timed pulse release composition |
| 10/05/2011 | EP1355676B1 Method of protecting therapeutic compositions from host-mediated inactivation |
| 10/05/2011 | EP1295607B9 Antitumor effect potentiators |
| 10/05/2011 | EP1267945B1 Genetically modified cells expressing a tgf-beta inhibitor, the cells being lung cancer cells |
| 10/05/2011 | EP1017835B1 Cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 10/05/2011 | CN1946407B Methods and composition for treating tumors and metastatic disease |
| 10/05/2011 | CN1817883B New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 10/05/2011 | CN102209727A Anti-tgf-beta receptor ii antibodies |
| 10/05/2011 | CN102209558A Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 10/05/2011 | CN102209549A Use of ammonium chloride in therapy |
| 10/05/2011 | CN102209547A Protein phosphatase inhibitor |
| 10/05/2011 | CN102209539A P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| 10/05/2011 | CN102209538A P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| 10/05/2011 | CN102206864A Agomelatine monocrystal with agomelatine VI crystal form, agomelatine mixed crystal with the agomelatine VI crystal form and preparation methods |
| 10/05/2011 | CN102206613A Acquisition and use of tumor-selective replicative adenovirus - thymidine kinase gene construct |
| 10/05/2011 | CN102206291A Process for extracting yam polysaccharide by using supercritical CO2 fluid extraction technique |
| 10/05/2011 | CN102206284A Recombinant human DT388sBAFF immunotoxin and coding gene and use thereof |
| 10/05/2011 | CN102206283A Recombinant human PE38sBAFF immunotoxin and coding gene and use thereof |
| 10/05/2011 | CN102206281A Fusion protein TETPH, expression vector and construction method thereof |
| 10/05/2011 | CN102206277A Antibodies that bind human interleukin-18 and methods of making and using |
| 10/05/2011 | CN102206276A Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin |
| 10/05/2011 | CN102206243A Medical application of ursolic acid-NF (Nuclear Factor)-kappaB inhibitor |
| 10/05/2011 | CN102206222A 2-fatty-amino-substituted indole quinoline derivative and preparation method and application thereof in preparation of antitumor drugs |
| 10/05/2011 | CN102206216A Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors |
| 10/05/2011 | CN102206206A Azabicyclooctane hydroximic acid derivatives, preparation method thereof, and application thereof in medicament |
| 10/05/2011 | CN102206203A Synthesis of benzimidazole-containing naphthalimide derivatives and applications of benzimidazole-containing naphthalimide derivatives on cancer resistance |
| 10/05/2011 | CN102206180A Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| 10/05/2011 | CN102206179A Bipyridine alkaloid compound and preparation method and use thereof |
| 10/05/2011 | CN102206177A 1-naphthyl benzophenone derivatives, and preparation method and application thereof |
| 10/05/2011 | CN102205118A Biological product and preparation method thereof |
| 10/05/2011 | CN102205059A Chinese herbal medicine composition for treating liver cancer, stomach cancer, lung cancer and leukemia and preparation method thereof |
| 10/05/2011 | CN102205035A Traditional Chinese medicine for treating gastric cancer |
| 10/05/2011 | CN102205002A Traditional Chinese medicine for treating intestinal cancer |
| 10/05/2011 | CN102204992A External application medicament for treating tumor |
| 10/05/2011 | CN102204978A Medicinal composition for treating cancer pain and preparation thereof |
| 10/05/2011 | CN102204974A Compound Chinese actinidia root Chinese medicinal composition and preparation method and application thereof |
| 10/05/2011 | CN102204951A Method for extracting active components from licorice |
| 10/05/2011 | CN102204950A Method for extracting flavonoid from liquorice waste residue |
| 10/05/2011 | CN102204942A Method for extracting corylus heterophylla leaf flavone |
| 10/05/2011 | CN102204939A Method for preparing pomegranate peel polyphenol liposome by reverse evaporation method |
| 10/05/2011 | CN102204936A Preparation method of total triterpene extract from poria cocos |
| 10/05/2011 | CN102204933A Preparation method of biological anti-tumor product |
| 10/05/2011 | CN102204927A Medicament for treating endoplasmic reticulum (ER) breast cancer |
| 10/05/2011 | CN102204924A Application of compound 6-O-angeloylplenolin to pharmacy |
| 10/05/2011 | CN102204921A Application of tetracycline derivative in preparing sensitizing drug for radiotherapy |
| 10/05/2011 | CN102204919A Application of bufotalin to preparation of medicament for treating intracranial tumors |
| 10/05/2011 | CN102204918A Steroid compound agonist for PPARgamma and its purpose |
| 10/05/2011 | CN102204913A Application of ligustrazine derivative to preparation of medicament for treating melanoma |
| 10/05/2011 | CN102204905A New applications of 8-oxy-8H-acenaphthene (1, 2-b) pyrrole derivatives |
| 10/05/2011 | CN102204903A Application of peperomin E and peperomin B compounds to medicament for suppressing angiogenesis |
| 10/05/2011 | CN102204902A Antrocin (Sesquiterpene lactones)-containing pharmaceutical composition for suppressing growth of cancer cells |